Clinical Trial
Clinical Trial
Clinical Trial Safety & Pharmacovigilance
Secure Your Clinical Studies with an Expert Partner in Clinical Pharmacovigilance and Regulatory Compliance
Clinical trial safety and pharmacovigilance represent critical regulatory requirements aimed at ensuring patient safety and compliance of clinical studies with health authority expectations.
Within a framework governed by the European Regulation No. 536/2014 (Clinical Trial Regulation – CTR), Good Clinical Practices (ICH E6), and ICH E2A to E2F guidelines, sponsors are required to maintain rigorous oversight of safety data throughout the entire clinical development lifecycle.
Regulatory responsibilities related to clinical pharmacovigilance apply to:
– Pharmaceutical companies
– Biotech firms
– Academic institutions
– CROs
– Medical device and healthcare product manufacturers
Atessia Vigilances supports sponsors in the comprehensive management of clinical trial pharmacovigilance activities for Phase I, II, III, and IV studies across France and Europe.
Our objective: to secure your regulatory obligations, ensure the quality of your safety data, and maintain regulatory compliance of your clinical studies through inspection readiness.
SAE & SUSAR Management
Secure the Management of Serious Adverse Events
We provide comprehensive management of serious adverse events occurring during clinical trials in compliance with international regulatory requirements.
Nos équipes assurent :
- collection, prioritization, duplicate checks, registration, and data entry of SAEs (Serious Adverse Events)
- medical and regulatory assessment of cases
- causality assessment and expectedness analysis
- identification of SUSARs (Suspected Unexpected Serious Adverse Reactions)
- follow-up management and case completeness
- expedited reporting (Day 7 / Day 15) through EudraVigilance
- notifications to competent authorities and Ethics Committees when required
Strict management of regulatory timelines combined with fully traceable and inspection-ready safety data processes.
Query Management & Investigator Communication
Strengthen the Quality and Consistency of Your Safety Data
The quality of safety data relies on reliable data collection and effective communication with investigative sites.
Atessia Vigilances supports:
- pharmacovigilance query management related to eCRF data
- targeted follow-up activities for critical safety data
- communication with investigators and clinical sites
- coordination with CRA, data management, and medical teams
- centralization of safety information
A structured approach designed to improve the quality, consistency, and completeness of safety data.
DSUR Preparation & Regulatory Reporting
Produce Robust and Compliant Safety Reports
Sponsors are required to ensure continuous monitoring of the benefit-risk profile of their clinical studies.
Our experts support the preparation of:
- DSURs (Development Safety Update Reports) in compliance with ICH E2F
- Periodic safety reports
- Cumulative pharmacovigilance data analyses
- Signal detection activities benefit-risk evaluations
Robust reports aligned with international standards and ready for submission to health authorities.
Regulatory Support & Safety Strategy
Secure Your Projects from the Earliest Development Stages
Clinical trial safety must be integrated from the earliest stages of development.
Atessia Vigilances supports sponsors with:
- drafting and review of protocol safety sections
- contributions to Investigator’s Brochures
- implementation of clinical trial pharmacovigilance procedures
- drafting of SAE Report Forms
- development of Safety Management Plans
- strategic regulatory compliance consulting
Regulatory expertise designed to secure your safety strategy from the design phase of your clinical studies.
Inspection & Audit Readiness
Anticipate EMA, ANSM, and International Health Authority Expectations
Clinical pharmacovigilance inspections require robust organization and strong documentation oversight.
Our teams support:
- pharmacovigilance and GCP documentation reviews
- gap assessments and audit readiness activities
- preparation for EMA and ANSM inspections
- remediation of processes and documentation
- preparation of teams and safety systems
A proactive approach designed to sustainably reduce your regulatory risk exposure.
An Inspection-Ready Organization
Atessia Vigilances applies methodologies based on:
- documented procedures
- full activity traceability
- adapted quality controls
- workflows aligned with regulatory requirements
- safety governance compliant with international standards
Our activities are designed to comply with:
- the Clinical Trial Regulation (CTR)
- ICH guidelines
- Good Clinical Practices (GCP)
- EMA and ANSM requirements
An organization designed to secure your clinical studies and effectively support regulatory inspections.
Why Choose Atessia Vigilances for Your Clinical Trials?
Recognized Expertise in Clinical Pharmacovigilance
Experienced consultants specialized in safety data management and clinical trial regulatory compliance.
Strong Knowledge of International Regulatory Requirements
Compliance with EMA, ANSM, CTR, ICH E2A-E2F, and GCP expectations.
An Inspection-Ready Approach
Processes and deliverables designed to support audits and inspections by health authorities.
A Flexible and Integrated Organization
- Full outsourcing or targeted support
- Integration with your internal teams or CROs
- Adaptation to study size, phase, and complexity
- Multi-country support
Operational and Strategic Expertise
A combined approach integrating operational management, quality oversight, and regulatory governance.
What You Gain by Working with Us
- Enhanced protection of patients and study participants
- Improved quality of clinical safety data
- Optimization of internal resources
- Enhanced preparedness for EMA and ANSM inspections
– Dedicated operational and regulatory expertise
Looking for an Expert Partner in Clinical Trial Pharmacovigilance?
Atessia Vigilances supports pharmaceutical companies, biotech firms, CROs, and academic institutions in managing their clinical pharmacovigilance obligations across France and Europe.